Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Montemurro

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantationY S Kim, S N Konoplev, F Montemurro, et al.
ESMO Open|December 15, 2023
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysisA Rizzo, F M Schipilliti, F Di Costanzo, et al.
Waste Management (New York, N.Y.)|June 13, 2020
How do novel and conventional agri-food wastes, co-products and by-products improve soil functions and soil quality?M T Gebremikael, A Ranasinghe, P S Hosseini, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Accelerated partial breast irradiation using 3D conformal radiotherapy: toxicity and cosmetic outcomeM Gatti, R Ponzone, S Bresciani, et al.
Cancer|January 21, 2000
Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin diseaseM Aglietta, F Montemurro, F Fagioli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>F Montemurro, S Delaloge, C H Barrios, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 2006
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancerF Montemurro, M Gatti, S Redana, et al.
British Journal of Cancer|November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trialsE Geuna, D Roda, S Rafii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2007
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)F De Vita, F Giuliani, M Orditura, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantationY S Kim, S N Konoplev, F Montemurro, et al.
ESMO Open|December 15, 2023
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysisA Rizzo, F M Schipilliti, F Di Costanzo, et al.
Waste Management (New York, N.Y.)|June 13, 2020
How do novel and conventional agri-food wastes, co-products and by-products improve soil functions and soil quality?M T Gebremikael, A Ranasinghe, P S Hosseini, et al.
Breast (Edinburgh, Scotland)|August 21, 2013
Accelerated partial breast irradiation using 3D conformal radiotherapy: toxicity and cosmetic outcomeM Gatti, R Ponzone, S Bresciani, et al.
Cancer|January 21, 2000
Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin diseaseM Aglietta, F Montemurro, F Fagioli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial<sup>☆</sup>F Montemurro, S Delaloge, C H Barrios, et al.
Journal of Chemotherapy (Florence, Italy)|April 1, 2006
Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancerF Montemurro, M Gatti, S Redana, et al.
British Journal of Cancer|November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trialsE Geuna, D Roda, S Rafii, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 26, 2007
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)F De Vita, F Giuliani, M Orditura, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 15, 2020
Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET populationE Ciruelos, G Jerusalem, M Martin, et al.
Pageof 4